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The Potency of AG10 in Stabilizing Transthyretin is Driven by Interactions Mimicking the
Disease-suppressing T119M Variant

Abstract

by Dengpan Liang
University of the Pacific
2019

Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no
available disease-modifying therapies. While destabilizing TTR mutations increase the risk of
developing ATTR-CM, the naturally occurring Thr119Met (T119M) variant stabilizes TTR
and prevent disease. The two Serine 117 and Serine 117’ (S117/S117’) side chain hydroxyl
groups of monomers A and B in T119M variant TTR form direct hydrogen bonds with each
other. AG10 is an orally available, small molecule TTR stabilizer in Phase 3 clinical
development for ATTR-CM. Structural features that infer high potency of AG10 for
stabilizing TTR remains incompletely characterized.
In order to investigate the contribution of hydrogen bonds between the pyrazole ring
of AG10 and the two S117/S117’ and the salt bridges between carboxyl group and two Lysine
15 and Lysine 15’ (K15/K15’) on the stabilization of TTR, we synthesized three AG10
analogues (compounds 1, 2, and 3). Isothermal titration calorimetry (ITC) was used to
determine the binding affinities (Kd) of ligands to TTR. Biochemical studies were used to
compare the potency of AG10 relative to other ligands in stabilizing TTR in buffer and
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human serum.
Results highlight the crucial roles played by the carboxyl group and pyrazole ring of
AG10 and the importance of the hydrogen bonds it forms with the two TTR dimers,
mimicking the interactions in the protective T119M-TTR mutation and enhancing the kinetic
stability of the TTR tetramer.
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Chapter 1: General Introduction

Transthyretin
Transthyretin (TTR, also called pre-albumin) is a protein that circulates in blood and
cerebrospinal fluid (CSF). TTR is synthesized by liver and secreted into blood, where it acts
as a backup carrier of thyroxine (T4) (<1% bound) and a primary carrier of retinol (vitamin A)
through its interaction with holo-retinol-binding protein (RBP) [1, 2].
The normal range of TTR concentration in blood is between 3.5 to 7 μM while in CSF
the concentration is around 500 nM [3].
Structure of TTR
Human TTR is a 55 kDa homotetrameric protein with four identical monomers. Each
TTR monomer consists of 127 amino acid residues, which forms an extensive β-sheet
structure (Figure 1.1) [4, 5]. The four identical subunits (or monomers) of TTR form an
internal channel at the weaker dimer-dimer interface where two T4 molecules can bind to the
resulting tetramer [6]. In addition to the thyroid hormones (T4) and its metabolites, other
pharmacologic agents and natural products, such as plant flavonoids, and nonsteroidal
analgesic drugs can also bind in the T4 for binding sites of TTR [7].
The structure of TTR was one of the first proteins determined by X-ray
crystallography [8]. Up to March 2019, there are 292 TTR crystal structures and their variants
listed in the Protein Data Bank (PDB, www.rcsb.org) includes 5 species (human, rat, mouse,
chicken, and fish). It is reported that the similarity of the amino acid sequence of TTR among
species is around 85%. However, the T4 binding site remains highly conserved. As shown in
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Figure 1.2, each TTR subunit (monomer) is made up of eight beta strands, denoted as A to H,
and one short alpha helix. These eight β-strands form two β-sheets, consisting of D-A-G-H
and C-B-E-F strands, together forming a β-barrel-like immunoglobulin structure. Two
monomers form a dimer mainly through an anti-parallel backbone and the backbone
interactions formed by H-chain, and through the interactions between the side chains and the
interconnected water molecules formed by the F-chain. These dimers then interact to form
tetramers through hydrophobic interactions between the AB and GH loops, creating
hydrophobic channels between the dimers where T4 binds [9]. The T4 binding site can be
divided into three halogen binding pockets (HBP), namely HBP1, HBP2, and HBP3. HBP1
forms the outermost part of the channel and consists of the side chains of Met13, Lys15, and
Thr106. HBP2 forms the middle portion of the channel consisting of the side chain of Leu17,
Ala109, Leu110 and the hydrophilic backbone carbonyl of Ala108 and Ala109. HBP3 forms
the last and innermost part of the channel and contains the side chains of Ala108, Ala109,
Leu110, Ser117, and Thr119. The hydrophilic portion of HBP3 is formed by the side chain of
Ser117 and Thr119 and the main chain carbonyl and amino groups of Ala108, Ala109,
Leu110 and, Thr118.
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Figure 1.1: Crystal structure of TTR with monomers colored individually.

Figure 1.2: TTR bound to T4 and holo-Retinol–binding protein (holo-RBP).
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TTR Mutations and Amyloidosis Diseases
TTR is a functional protein which benefit our body. However, it can also cause serious
diseases. TTR is one of many proteins which can aggregate and form amyloid fibril in soft
tissue, nervous system, and solid organs and lead to diseases due to some genetic mutations
destabilizing the structure of protein [10]. The disassociation, misfolding, and aggregation of
TTR is the major cause of amyloid-related diseases such as familial amyloid cardiomyopathy
(FAC) [11, 12], familial amyloid polyneuropathy (FAP)[13, 14], and senile systemic
amyloidosis (SSA) [15].
Transthyretin (TTR) amyloidosis (ATTR) is a progressive, fatal disease in which
deposition of amyloid derived from either mutant (TTRm) or wild-type (TTRwt) TTR causes
severe organ damage and dysfunction [16, 17]. Clinically, ATTR presents as cardiomyopathy
(ATTR-CM) or peripheral polyneuropathy (ATTR-PN). The most prevalent mutation that
causes ATTRm-CM is the V122I variant, carried by around 1.3 million of African Americans,
which increases the risk of ATTR-CM several-fold in this population [18, 19]. The number
of the carrier is huge and this may influence millions of families. Thus, we focus on ATTRCM here. ATTR-CM is infiltrative, restrictive cardiomyopathy characterized by progressive
left and right heart failure. Familial ATTR-CM (ATTRm-CM) is driven by pathogenic,
autosomal dominant, point mutations resulting in amino acid substitutions that destabilize the
native TTR tetramer, prompting its dissociation [20, 21] by either reducing their
thermodynamic stability, or by reducing the kinetic barrier of tetramer dissociation, or both
[22]. There are over 100 known amyloidogenic mutations in the TTR that are classified as
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ethnic and geographical groups [23, 24].In addition, older individuals may develop ATTR
derived from wild-type TTR (ATTRwt-CM). The average life expectancy for people with
ATTR-CM is 3−5 years from diagnosis [25]. Unfortunately, ATTR-CM represents one of the
largest genetically defined diseases with no approved disease-modifying therapies. The TTR
tetramer features two largely unoccupied thyroxine (T4)-binding sites that are formed
between adjacent monomers at the weaker dimer−dimer interface of TTR. Tetramer
dissociation into dimers, and then monomers, is the initial and rate-limiting step in TTR
amyloidogenesis [16]. The majority of TTR mutations increase the amyloidogenic potential
of TTR by lowering its thermodynamic stability and/or decreasing the kinetic barrier for
tetramer dissociation [26].
ATTR-CM Therapy
Unfortunately, for TTR cardiomyopathy there is no FDA-approved drugs are currently
available. Only the heart transplant cannot cure the disease inherently. Liver transplantation,
that removes the origin of the mutated protein, has been the treatment of alternative for TTR
amyloidosis [27]. Combined liver and heart transplantation is performed as palliative therapy
for a subset of FAC patients [28]. the risk and price of organ transplantation are substantial
and transplant patients need lifelong use of immune-suppressive medication resulting in
morbidity. For these reasons, there's an imperative need for a medical specialty treatment of
TTR cardiomyopathy. Diflunisal was repurposed drug that was investigated in ATTR-CM. In
addition, tafamidis is a TTR stabilizer for ATTR-CM in Phase 3 currently. Unluckily, while
diflunisal could not pass the clinical Phase 3 trial due to the side effects, tafamidis has a low
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comparable efficacy [10].

Figure 1.3: Chemical structure of Tafamidis and Diflusinal.

TTR Stabilizing Mutations
Two TTR variants, T119M and R104H, have been shown to prevent amyloidogenesis
in vitro [29, 30]. Individuals who are compound heterozygous for both the T119M variant
and the polyneuropathy associated V30M−TTR mutation present a more benign evolution of
ATTR-PN or no disease compared to kindred carrying the V30M−TTR mutation alone [31].
In addition, carriage of the T119M rescue mutation in the absence of other destabilizing TTR
mutations has been correlated with a decreased risk of vascular disease and increased life
expectancy, as compared to the general (non-carrier) population, by 5−10 years [32]. Similar
effects have been described for the R104H−TTR variant in Japanese individuals expressing
both R104H and V30M− TTR [33]. The trans-suppressor effects of T119M and R104H are
based on different mechanisms [30]. While the T119M kinetically stabilizes the quaternary
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structure of TTR, increasing the energy barrier of dissociation, the R104H variant is
thermodynamically stabilized. Therefore, the stabilizing effect of the T119M mutation is
much greater than that of R104H, which only modestly protects against TTR dissociation and
aggregation in vitro. We know nature is the best teacher for human beings. Can we learn
something about drug design from it?
TTR Stabilizer AG10
It is reported that dissociation of the TTR-tetramer at the T4-binding interface is the
rate-limiting step and kinetic stabilizers which binds tightly to the T4 pockets can raise the
dissociative transition state energy and slow/halt disease [34]. Previously, Alhamadsheh et al.
developed the first high-throughput screening (HTS) of TTR ligands, which enabled the
identification of various potent and structurally distinct TTR kinetic stabilizers [35]. Our lab
used these kinetic stabilizers as lead compounds to perform structure activity correlation
(SAR) studies. The activity of the synthesized compounds was compared to that of the
clinical drug candidates for TTR amyloidosis, tafamidis and diflunisal. Among the
synthesized compounds, AG10 was the most potent and selective stabilizers for TTR (Figure
1.3). Studies have shown that AG10 completely stabilized the V122I-TTR variant in the
serum of patients with FAC. AG10 was also effective in protecting human cardiomyocytes
from the toxic effects of TTR amyloid. AG10 has successfully completed a Phase 2 clinical
trial for ATTR-CM and currently being examined in Phase 3 clinical trial. It will probably
bring gospel to patients who are suffering from this fatal disease. X-ray crystallography
reveals important insights on how AG10 bind to V122I-TTR with high affinity and
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kinetically stabilize the tetramer. In the crystal structure as shown (Figure 1.4 a.), the
carboxylic acid group of AG10 has short distance between K15/K15’. The pyrazole ring of
AG10 has short distance with the hydroxyl side chain serine 117 (S117) and S117′ (Figure 1.4
a.) (distance ~2.8 Å) of adjacent monomers in the low dielectric macromolecular interior of
the T4 binding site (Figure 1.4). These potentially forming hydrogen bonds by pyrazole ring
and S117/S117’ are likely to be responsible for the driving force for the dominant enthalpic
binding of AG10 to TTR. Remarkably, similar hydrogen bonds have been reported within the
inner cavity of the kinetically stabilizing trans-suppressor T119M-TTR variant (Figure 1.4 b.)
[36, 37].

Figure 1.4: Chemical structure of the TTR stabilizer, AG10.
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Figure 1.5: Crystal structures of AG10 and TTR.They highlight similar interactions caused by
the T119M mutation and binding of AG10 to TTR. (a) Quaternary structure of AG10 bound
to V122I-TTR (PDB: 4HIQ)[10]. (b) Crystal structure of the stabilizing T119M-TTR variant
(PDB: 1FHN) [37]. (c) Crystal structure of TTRwt (PDB: 3CFM) [38]. (d) Crystal structure
of thermodynamically stabilized R104H-TTR (PDB: 1X7T) [39].

Hypothesis
Since both T119M and AG10 increase the energy barrier of the dissociation of TTR.
What is the relationship between them? Does AG10 learn from natural mutation T119M? And
do these groups mimic the T119M stabilizing TTR. Here we come up with our hypothesis:
These two groups predominantly contribute to AG10’s efficacy, mimicking TTR stabilizing
mutation. One is the carboxylic group on benzine ring which might form salt bridge with
K15/K15’. The other are the two amine groups in the pyrazole ring which might form two
hydrogen bonds with S117/S117’ (Figure 1.3).
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Chapter 2: Synthesis of AG10 Analogues 1, 2, and 3

2.1 AG10 Analogues Design
In order to prove our hypothesis, we designed a series of AG10 analogues shown in
Figure 2.1 (AG10 analogue 1, 2, and 3). By blocking the carboxylic group, it will prevent
carboxylic group forming a salt bridge with Lys15. Thus, we can test the contribution of the
carboxylic group to AG10. In order to minimize space hinderance, we choose methyl-ester.
Therefore, we designed AG10 analogue 1 which has a methyl-ester. By blocking one amine
group in the pyrazole ring, it will prevent one amine group forming a hydrogen bond with
Ser117, and it can form only one hydrogen bond with one of the adjacent TTR subunits. With
this, we can test the contribution of one amine group to AG10. In order to minimize space
hinderance, we choose the N- methyl group. Therefore we designed AG10 analogue 2 which
has an N-methyl pyrazole. By increasing the distance between amine groups in the pyrazole
ring to Ser117, it will prevent forming any hydrogen bond between them. Thu we can test the
contribution of these two amine groups. Modeling studies suggested that the bulk of the
diethyl groups would prevent the molecules from reaching deep in the T4-binding site,
thereby reducing the possibility of forming any hydrogen bonds with S117/S117′. Therefore,
we also designed AG10 analogue 3 where the dimethyl pyrazole of AG10 was replaced by
diethyl pyrazole.
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Figure 2.1: Chemical structure of AG10, analogue 1, 2, and 3.

2.2 Materials and Methods
All the reactions were carried out under an argon or nitrogen atmosphere using dry
solvents under anhydrous conditions unless mentioned otherwise. The solvents used were
ACS grade and bought from Fisher. Reagents were purchased from Aldrich and Fisher and
used without further purification. Reactions were monitored by thin-layer chromatography
(TLC) carried out on 0.20 mm POLYGRAM® SIL silica gel plates (Art.-Nr. 805 023) with
fluorescent indicator UV254 using UV light as a visualizing agent. Normal phase flash
column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher). 1H
NMR and 13C NMR spectra were recorded on a Jeol JNM−ECA600 spectrometer and
calibrated using a residual undeuterated solvent as an internal reference. Coupling constants
(J) were expressed in Hertz. The following abbreviations were used to explain the
multiplicities: s = singlet, d = doublet, t =triplet, q = quartet, m = multiplet. Low-resolution
mass spectra ESI by Varian 320. High-resolution mass spectra (HRMS) were recorded by
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JEOL DART AccuTOF (Direct Analysis in Real Time). HPLC analysis was performed on
Agilent 1100 series HPLC system connected to a diode array detector operating between the
UV ranges of 200 – 400 nm and quantified using Agilent Chemstation software. The HPLC
analysis was performed on both Waters™ XBridge C18 column (4.6 X 250 mm, 5μm) and
Waters™ Symmetry300 C4 column (2.1 X 150 mm, 5 µm) at ambient temperature upon
injection of a 50 μL each of Blank buffer, standard and/or sample to obtain the
chromatogram. The mobile phase was composed of solvent A consisting methanol-water
(5:95, v/v) containing 0.1% formic acid and solvent B consisting methanol-water (95:5, v/v)
containing 0.1% formic acid. The HPLC program was a gradient separation method
increasing linearly from 0% to 100% solvent B from 0 to 20 min and then maintained 100%
solvent B up to 30 min.
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2.3 Synthetic Procedures
All AG10 analogues were prepared as described below.
2.3.1 Synthesis of AG10 analogue compound 1.

Figure 2.2: Synthesis of AG10 analogue compound 1.

Methyl 3-(3-bromopropoxy)-4-fluorobenzoate (4): compound 4 was synthesized as
reported earlier[10]. To a solution of methyl 4-fluoro-3hydroxybenzoate (1.0 g, 5.87 mmol, 1
equiv) and 1,3-dibromopropane (3.0 ml, 29.4 mmol, 5 equiv) in DMF (15 ml) was added
K2CO3 (0.98 g, 7.1 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature
for 16 hours. The mixture was diluted with EtOAc (500 mL), washed with brine (3x200 mL)
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and dried with Na2SO4. The solution was filtered and concentrated. The residue was purified
by flash column chromatography (silica gel, 1-10% EtOAc/hexanes) to produce compound 4
(1.3 g, 76% yield); 1H NMR (CD3OD, 600 MHz) δ 7.67-7.61 (m, 2H), 7.14-7.07 (m, 1H),
4.21 (t, 2H, J = 5.89 Hz), 3.89 (s, 3H), 3.62 (t, 2H, J = 6.38 Hz), 2.38-2.31 (m, 2H); (ESI+)
m/z: calcd for C11H12BrFO3 + H+ 290.00; found 290.01 (M + H+).

Methyl 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoate (1): To a
solution of acetylacetone (0.552 mL, 5.38 mmol, 2 equiv) and 1,8-Diazabicyclo[5.4.0]undec7-ene (DBU) (0.804 mL, 5.38 mmol, 2 equiv) in benzene (7 mL), methyl 3-(3bromopropoxy)-4-fluorobenzoate 4 (780 mg, 2.69 mmol, 1 equiv) in benzene (3 ml) was
added dropwise. The reaction mixture was stirred at room temperature for 72 h. The mixture
was filtered and concentrated. The residue was purified by flash column chromatography
(silica gel, 1-10% EtOAc/hexanes) to produce the alkylated intermediate (5) which was used
in the next step directly. To a solution of this intermediate in ethanol (5 mL) hydrazine
hydrate (0.36 mL, 6.73 mmol, 2.5 equiv) was added and the reaction was heated under reflux
for 4 h. The reaction was concentrated and purified by flash column chromatography (silica
gel, 1-20% MeOH/CH2Cl2) to afford compound 1 (288 mg, 35% yield); (96.3% purity by
HPLC): tR (column) (C18) = 25.11 min; t R (C4) = 14.03 min. 1H NMR (CD3OD, 600 MHz) δ
7.63-7.58 (m, 2H), 7.19-7.15 (m, 1H), 4.00 (t, 2H, J = 6.0 Hz), 3.86 (s, 3H), 2.58 (t, 2H, J =
7.2 Hz), 2.12 (s, 6H), 1.97-1.92 (m, 2H). 13C NMR (CD3OD, 600 MHz) δ 168.1, 158.4,
156.7, 148.9, 128.5, 124.6, 117.6, 117.0, 115.6, 69.4, 53.3, 31.1, 20.2, 10.9; HRMS (DART)
m/z: calcd for C16H19FN2O3 + H+ 307.1458; found 307.1463 (M+H+).
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Figure 2.3: HPLC trace of compound 1 in C4 column (>96% purity).

Figure 2.4: HPLC trace of compound 1 in C18 column (>96% purity).
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Figure 2.5: MS data of compound 1.
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2.3.2 Synthesis of AG10 analogue compound 2.

Figure 2.6: Synthesis of AG10 analogue compound 2.

4-fluoro-3-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (2): To a
solution of 1 (21 mg, 0.07 mmol, 1 equiv) in DMF (3 ml) sodium hydride (5 mg, 0.21 mmol,
3 equiv) and methyl iodide (17 µl, 0.28 mmol, 4 equiv) was added. The reaction mixture was
stirred at room temperature for 2 hr. The mixture was extracted with brine, filtered and
concentrated. The residue was purified by flash column chromatography (silica gel, 0.5-2%
MeOH/EtOAc) to produce the alkylated intermediate (6) which was used in the next step
directly. Sodium hydroxide (5.6 mg, 0.14 mmol, 2 equiv) in water (0.5 mL) was added to a
solution of alkylated intermediate in methanol (2 mL) and the reaction was heated at 50°C
under reflux for 4 hr. The reaction was concentrated and purified by preparative HPLC with
buffer solvent A and B (buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B:
methanol, water, TFA at ratio 95:5:0.1) using C18 column to afford compound 2 (9.8 mg,
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46% yield for two steps); (97.8% purity by HPLC): t R (column) (C18) = 25.25 min; t R (C4) =
15.71 min.1 H NMR (CD3OD, 600 MHz) δ 7.58-7.51 (m, 2H), 7.10-7.06 (m, 1H), 3.92 (t, 2H,
J = 6.0 Hz), 3.56 (s, 3H), 2.49 (t, 2H, J = 7.2 Hz), 2.05 (s, 3H), 2.01 (s, 3H), 1.83-1.88 (m,
2H). 13C NMR (CD3OD, 600 MHz) δ 168.1, 154.6, 146.8, 145.3, 137.2, 128.1, 122.8, 115.5,
115.4, 114.8, 67.4, 34.3, 29.4, 18.8, 10.1, 7.9; HRMS (DART) m/z: calcd for C 16H19FN2O3 +
H+ 307.1458; found 307.1449 (M+H+).

Figure 2.7: HPLC trace of compound 2 in C4 column (>96% purity).

Figure 2.8: HPLC trace of compound 2 in C18 column (>96% purity).
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Figure 2.9: MS data of compound 2.
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2.3.3 Synthesis of AG10 analogue compound 3.

Figure 2.10: Synthesis of AG10 analogue compound 3.

Methyl 3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoate (8): To a
solution of a mixture solution of 3,5-heptanedione (95 μL, 0.7 mmol, 2 equiv) and DBU (104
μL, 0.7 mmol, 2 equiv) in benzene (5 mL), methyl 3-(3-bromopropoxy)-4-fluorobenzoate
(4)[40] (100 mg, 0.35 mmol, 1 equiv) in benzene (2 mL) was added dropwise. The reaction
mixture was stirred at room temperature for 72h. Then the mixture was filtered and
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concentrated. The residue was purified by flash column chromatography (silica gel, 1-10%
EtOAc/hexanes) to produce the alkylated intermediate (7) which was used in the next step
directly. To a solution of this intermediate in ethanol (5 mL) was added hydrazine hydrate (47
μL, 0.875 mmol, 2.5 equiv) and the reaction mixture was stirred at 90 ℃ for 4 h under reflux.
The mixture was diluted with EtOAc (30 mL), washed with brine (3x10 mL) and dried with
Na2SO4. The organic layers were combined and were filtered and concentrated. It was
purified by flash column chromatography (silica gel, 1-5% MeOH/EtOAc) to afford
compound 8 (75 mg, 65% yield for two steps); 1 H NMR (CD3OD, 600 MHz) δ 7.59-7.54 (m,
2H), 7.15-7.11 (m, 1H), 3.98 (t, 2H, J = 6.0 Hz), 3.81 (s, 3H), 2.56-2.47 (m, 6H), 1.91-1.86
(m, 2H), 1.13 (t, 6H, J=7.8 Hz). 13C NMR (CD3OD, 600 MHz) δ 167.9, 156.6, 156.2, 148.8,
148.7, 124.4, 117.5, 117.3, 116.9, 113.9, 69.5, 53.1, 31.8, 20.1, 14.7; HRMS (DART) m/z:
calcd for C18H23FN2O3 + H+ 335.1771; found 335.1773 (M+H+).

3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (3): To a solution of
8 (13 mg, 0.04 mmol, 1 equiv) in methanol (2 mL) sodium hydroxide (3.2 mg, 0.08 mmol, 2
equiv) in water (0.5 mL) was added and the reaction was heated at 50°C under reflux for 4 hr.
The reaction was concentrated and purified by flash column chromatography (silica gel, 15% MeOH/EtOAc) to produce compound 3 (10 mg, 80% yield); (96.0% purity by HPLC): t R
(column) (C18) = 25.16 min; t R (C4) = 15.56 min. 1H NMR (CD3OD, 600 MHz) δ 7.57-7.49
(m, 2H), 7.08-7.04 (m, 1H), 3.94 (t, 2H, J = 6.0 Hz), 2.51-2.43 (m, 6H), 1.87-1.82 (m, 2H),
1.06 (t, 6H, J=7.8 Hz). 13C NMR (CD3OD, 600 MHz) δ 169.8, 157.9, 156.3, 149.3, 148.5,
124.6, 117.2, 117.1, 114.1, 69.4, 31.8, 20.1, 19.9, 14.7; HRMS (DART) m/z: calcd for
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C17H21FN2O3 + H+ 321.1614; found 321.1601 (M+H+).

Figure 2.11: HPLC trace of compound 3 C4 column (>96% purity).

Figure 2.12: HPLC trace of compound 3 C18 column (>96% purity).
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Figure 2.13: MS data of compound 3.
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Chapter 3: Evaluation of Activity of AG10 Analogues in Stabilizing TTR in Buffer and
Human Serum

3.1 Statistical Analysis
All results are expressed as mean±SD, all statistical analysis was performed with
GraphPad PRISM software. The significance of the differences was measured by one-way
ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤
0.01; ***p ≤ 0.001).
3.2 Materials
The probe was synthesized by our lab. Human male AB plasma, Sigma; catalog no.
H4522. The solvents used were ACS grade from Fisher. Reagents were purchased from
Aldrich and Fisher.
3.3 Evaluation of the Binding Affinity of AG10 Analogues to TTR by Isothermal
Titration Calorimetry (ITC)
By only analyzing the crystal structures of AG10 and TTR, the interaction between
them cannot be confirmed. However, Isothermal Titration Calorimetry (ITC) can provide the
insight information of H-bonding, and electrostatic interactions mediate binding. ITC is an
instrument for measuring thermal dynamic parameters such as Kd (binding affinity), ΔG
(Gibbs free energy), ΔH (enthalpy) and ΔS (entropy). The Kd for binding of a stabilizer to
TTR is represented by the change in Gibbs free energy of binding (ΔG), where ΔG = ΔH −
TΔS. By
analyzing the thermodynamic signature of each molecule, we can assess the relative
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contributions of enthalpic (ΔH; representing the formation or breaking of chemical bonds)
and entropic forces Here, we conducted the ITC experiment to identify the interaction
between AG10 and K15/K15’, Ser117/S117’by analyzing AG10 itself and AG10 analogue 1,
2 and 3.
3.3.1 Methods. Binding experiments were performed using MicroCal PEAQ-ITC at
25 °C. A solution of ligand (25 μM in PBS pH 7.4, 100 mM KCl, 1 mM EDTA, 2.5%
DMSO) was prepared and titrated into an ITC cell containing 2 μM of TTR in an identical
buffer. 19 injections of ligand (2.0 μL each) were injected into the ITC cell (at 25oC) to the
point that TTR was fully saturated with ligand. Calorimetric data were plotted and fitted
using the standard single-site binding model by which we get ΔG, ΔH, ΔS and Kd values.
For control, we tested the enthalpy change caused by titrating DMSO in buffer into TTR and
the resulting binding enthalpies was < 0.4 kcal/mol.
3.3.2 Results. In order to test the interaction between carboxylic acid moiety on the
para-fluoro-aryl ring of AG10 and K15/K15’, we tested the methyl-ester analogue of AG10
(compound 1, Fig. 3.2 a) In the ITC experiment, compound 1 displayed significantly lower
enthalpy (ΔH = -6.49 kcal/mol) to TTR compared to AG10 (ΔH = -13.6 kcal/mol). This result
suggested the lower strength interactions between the ester group of 1 and K15/K15’
compared to the salt bridge in AG10. This can be explained by losing the salt bridge of
analogue 1 and K15/K15’. And the loss of interaction resulting in a lower binding affinity (Kd
= 258 ± 17nM) to TTR in buffer compared to AG10 (Kd = 4.8 ± 1.9 nM).
In order to test the interaction between 3,5-dimethyl-1H-pyrazole ring moiety on the

39

para-fluoro-aryl ring of AG10 and S117/117’, we tested the N-methyl pyrazole analogue of
AG10 (compound 2, Fig. 3.2 a) In the ITC experiment, compound 2 displayed significantly
lower enthalpy (ΔH = -4.73 kcal/mol) to TTR compared to AG10 (ΔH = -13.6 kcal/mol). In
order to confirm the interactions between the pyrazole ring and S117/S117’, we also tested
compound 3 where the dimethyl pyrazole of AG10 was replaced with diethyl pyrazole. Result
showed greatly reduced enthalpy (ΔH = -2.1 kcal/mol) contribution of binding to TTR
compared to AG10 (ΔH = -13.6 kcal/mol). These data indicate there are interactions between
the two amine groups in the pyrazole ring and S117/S117’. Blocking the N-methyl group
would prevent the pyrazole ring of 3 to form one hydrogen bond with one of the adjacent
TTR subunits (Figure 3.2 a). And the bulk of the diethyl groups would prevent forming any
hydrogen bonds with S117/S117′. And the loss of H-bonds leads to a lower binding affinity
of analogue 2 (Kd = 251 ± 12 nM) and analogue 3 (Kd = 1253 ± 79 nM) to TTR.
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Figure 3.1: Thermodynamic parameters of AG10 and analogues. (a) Chemical structures and
in silico docking study of synthesized AG10 analogues 1, 2, and 3. Co-crystal structure of
AG10 bound to TTR used for the docking experiment. 1 is the methyl-ester form of AG10
that cannot form salt bridge with K15/15′. 2 is the methyl-pyrazole form of AG10 that can
potentially form only one hydrogen bond with either K15 or K15′. 3 is the diethyl-pyrazole
analogue of AG10 which affects both hydrogen bonds with S117/S117′. (b) Interaction of
TTR with analogues assessed by ITC. Thermodynamic data; ΔG are blue bars, ΔH are green
bars, and −TΔS are red bars.
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Table 3.1: Comparison of the binding affinity, thermodynamics, and potency of stabilizers to
TTR in buffer and human serum.

a

Stabilizers to TTR ratio. %TTR occupancy in buffer and human serum was determined by
FPE assay. %TTR stabilization in human serum was determined by Western blot by Mark.

3.4 Evaluation of the Binding Affinity of AG10 Analogues to TTR in Buffer

In order to confirm the binding affinity to TTR, we used the fluorescence probe
exclusion (FPE) assay as previously reported [40]. In this assay, a probe (Figure 3.1) was
used which has no fluorescence by itself, however, it forms a fluorescent conjugate and emits
fluorescence once it covalently binds to lysine 15 (K15) in the T 4 binding site of TTR.
Stabilizers that bind to the T4 site of TTR will decrease FPE probe binding as observed by
lower fluorescence. The lower fluorescence observed indicates a higher binding affinity of
the stabilizer.
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3.4.1 Methods. FPE with TTR in buffer: An aliquot of 98 µL of TTR in PBS (pH 7.4,
final concentration: 2.5 µM) was mixed with 1 µL of test compounds (final concentration: 2.5
µM) and 1 µL of FPE probe (0.18 mM stock solution in DMSO: final concentration: 1.8 µM).
The change in fluorescence (λex = 328 nm and λem = 384 nm) were monitored using a
microplate spectrophotometer reader (SpectraMax M5) for 6 h at room temperature.

Figure 3.2: Chemical structure of FPE probe.

3.4.2 Results. In the FPE assay, TTR occupancy represents how many percent of T4
binding pockets are occupied by stabilizers. The higher occupancy suggests a higher binding
affinity of stabilizers to the TTR compared to the probe. As shown in Table 1 and Figure 3.3,
by blocking the carboxylic group on the benzene, analogue 1 displayed reduced TTR
occupancy in buffer (38.5 ± 0.8%) compared to AG10 at the same concentration (2.5 µM).
By blocking amine groups, analogue 2 and 3 also displayed reduced TTR occupancy in buffer
(29.7 ± 0.7% and 17.2 ± 0.9% separately) compared to AG10 at the same concentration (2.5
µM).

% F P E P r o b e F lu o r e s c e n c e in b u ffe r
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Figure 3.3: binding affinity and selectivity of AG10 and analogues to TTR in human serum.
Fluorescence change caused by modification of TTR in buffer (2.5 μM) by FPE probe
monitored in the presence of probe alone (control DMSO) or TTR stabilizers (2.5 μM; 1:1
stabilizers to TTR ratio).
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Figure 3.4: TTR occupancy by AG10 and analogues in buffer. Bar graph representation of
percent occupancy of TTR in buffer by stabilizers in the presence of FPE probe measured
after 3 h of incubation relative to probe alone. Error bars indicate SD (n = 3).

3.5 Evaluation of the Binding Affinity and Selectivity of AG10 Analogues to TTR in
Human Serum
In order to stabilize TTR among more than 4,000 proteins present in the human body,
the stabilizers must be selectively bound to TTR. Therefore, the selectivity of these analogues
needs to be determined in human serum. This assay would have a better imitation of practical
efficacy.
3.5.1 Methods. FPE with TTR in human serum: An aliquot of 98 µL of pooled human
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serum (TTR concentration 5 μM) was mixed with 1 µL of test compounds [All compounds
were prepared as 10 mM stock solutions in DMSO and final concentration in the well were
10 μM] and 1 µL of FPE probe (0.36 mM stock solution in DMSO: final concentration: 3.6
µM).

3.5.2 Results. Similar to the result in the buffer, all the analogues showed a reduced
binding affinity and selectivity in human serum compared to AG10. As shown in Table 1 and
Figure 3.3, analogue 1 displayed reduced TTR occupancy in buffer (63.2 ± 2.5%) compared
to AG10 at the same concentration (2.5 µM). Analogue 2 and 3 also displayed reduced TTR
occupancy in buffer (43.0 ± 0.6% and 20.8 ± 3.3% separately) compared to AG10 at the same
concentration (2.5 µM). These results highlighted the important role of carboxylic group and
amine groups for the binding affinity and selectivity of AG10 again.
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Figure 3.5: Efficacy of stabilizers in occupying and stabilizing TTR in human serum. FPE
probe monitored in the presence of probe alone (control DMSO) or TTR stabilizers (10 μM;
2:1 stabilizers to TTR ratio).
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Figure 3.6: TTR occupancy by AG10 and analogues in human serum.
Bar graph representation of percent occupancy of TTR in human serum by stabilizers in the
presence of FPE probe measured after 3 h of incubation relative to probe alone. Error bars
indicate SD (n = 3).

3.6 Characterization of Key Functional Groups of AG10
The Kd for binding of a stabilizer to TTR is represented by the change in Gibbs free
energy of binding (ΔG), where ΔG = ΔH − TΔS. By analyzing the thermodynamic signature
of each molecule, we can assess the relative contributions of enthalpic (ΔH; representing the
formation or breaking of chemical bonds) and entropic forces (ΔS; associated with the
amount of disorder in a system and frequently dominated and favored by release of bound
water molecule due to hydrophobic interactions). To investigate the enthalpic contribution of
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each of the functional groups of AG10 on TTR binding and stabilization, we synthesized and
tested three AG10 analogues (compounds 1, 2, 3; Figure 3.2a) and evaluated their ability to
bind and stabilize TTR (Figures 3.3 ~3.6).

The carboxylic acid moiety of AG10 forms two salt bridges directly with the ε-amino
groups of K15 and K15′ at the periphery of the T4-binding site, which serves to close the T4
pocket around AG10 and partially shield it from the solvent. We synthesized a methyl-ester
analogue of AG10 (compound 1, Figure 3.2a) to test the effect of modifying the two salt
bridges that AG10 forms at the periphery of the T 4-binding site. Compound 1 displayed
significantly lower affinity (Kd = 258 ± 17 nM) to TTR in buffer compared to AG10 (Kd =
4.8 ± 1.9 nM), which could be explained by the lower strength of potential hydrogen bonds
between the ester group of 1 and K15/K15′ (ΔH = −6.49 kcal/mol) compared to the salt
bridge in AG10 (Figure 3.2b). Compound 1 also displayed reduced potency for TTR in buffer
and human serum compared to AG10 (Figures 3.3~3.6). The 3,5-dimethyl-1H-pyrazole ring
of AG10 sits deep within the inner cavity of the T4-binding site and forms two hydrogen
bonds with the S117 and S117′ of adjacent subunits[10]. By blocking these interactions, we
can effectively observe their enthalpic contribution using ITC and the FPE assay,
respectively. Therefore, we synthesized compound 2 which has an N-methyl pyrazole. The Nmethyl group would restrict the pyrazole ring of 2 to form only one hydrogen bond with one
of the adjacent TTR subunits (Figure 3.2a). We also synthesized compound 3 where the
dimethyl pyrazole of AG10 was replaced by diethyl pyrazole. Modeling studies suggested
that the bulk of the diethyl groups would prevent the molecules for reaching deep in the T4-
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binding site, thereby decreasing its ability to potentially form any hydrogen bonds with
S117/S117′ (Figure 3.2a). As predicted by modeling, both 2 (Kd = 251 ± 12 nM) and 3 (Kd =
1253 ± 79 nM) showed greatly reduced binding affinity to TTR in buffer. This reduced
affinity was translated into a significant decrease in potency for TTR in buffer and human
serum, especially for compound 3. The order of potency for stabilizing TTR was similar in
both buffer and serum (1 > 2 > 3; Figure 3.3~ 3.4). As we observed with the clinical ATTR
stabilizers, the potency of AG10 and compounds 1, 2, and 3 in occupying and stabilizing TTR
correlated very well (R2 = 0.98) with the binding enthalpy of these molecules (ΔH = -13.6,
−6.49, -4.73, and -2.1 kcal/mol, respectively). Interestingly, despite the similar binding
affinities of 1 and 2, their potency was significantly different (Table 1). The higher potency of
1 compared to 2 could be explained by its favorable enthalpic binding (ΔH = -6.49 kcal/mol
and -4.73 kcal/mol, respectively) (Figure 3.2b). This observation is similar to the data
obtained for AG10 and tafamidis [41]. These results highlight the crucial role played by the
pyrazole ring and the importance of the hydrogen bonds it forms with the two TTR dimers,
mimicking the interactions in the protective T119M-TTR mutation, and enhancing the kinetic
stability of the TTR tetramer.
3.7 Discussion
Optimizing the binding enthalpy of small molecules has been associated with the
development of second-generation drugs with improved selectivity [42, 43, 44].Enthalpic
forces have also been correlated with the stability of protein association complexes [45, 46].
The trans-suppressor T119M-TTR is a super-stabilizing variant compared to TTRwt (reported
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T119M-TTR dissociation rate is 40-fold slower than that of TTRwt) [29]. This variant
effectively ameliorates disease progression and symptoms in compound heterozygous
individuals carrying the pathogenic, destabilizing V30M mutation [31]. The T119M
substitution induces conformational changes that promote hydrogen bonding between the
hydroxyl groups of adjacent S117 residues of T119M-TTR monomers and lead to closer
contacts between the two dimers within the tetramer[37]. These enthalpically favorable
interactions and their consequences are neither observed in TTRwt nor in the
thermodynamically stabilized, disease-protective R104H variant, suggesting that they are
important for the enhanced kinetic stabilization of the TTR tetramer. Our studies show that
AG10’s enthalpically-driven mode of action is through kinetic stabilization of TTR, which is
similar to the kinetically stabilizing T119M variant and not comparable to the
thermodynamically stabilizing R104H. When comparing the T119M mutation to the cocrystal structure of AG10 bound to the kinetically destabilized V122I-TTR, the similarities of
these critical intramolecular interactions are evident and we conclude that AG10’s mode of
binding, especially the two hydrogen bonds with S117/S117’ that are buried in the low
dielectric macromolecular interior of the T4 pocket, may well explain AG10’s efficient
binding and stabilizing of tetrameric TTR. The experiments comparing closely related,
structural analogues of AG10 highlight the important role of the pyrazole ring of AG10 in
enthalpically driving the binding by forming two hydrogen bonds with different subunits of
TTR. These unique interactions with the S117/S117’ residues at the bottom of the T4 binding
pocket of TTR are not observed in other stabilizers. To the best of our knowledge, this is the
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first report describing a correlation between enthalpic binding of a ligand and enhanced
potency in stabilizing multi-protein complexes.
Similar to T119M-TTR, enthalpic forces have been reported to play a dominant role
in stabilizing the eye lens crystallin proteins. Analysis of the association energetics of βcrystallins (which associate into dimers, tetramers, and higher order oligomers) showed that
β-crystallins which associate by predominately hydrophobic forces participate in a weaker
protein associations whereas the formation of stable tetramers is dominated by enthalpicallydriven interactions between the subunits (mediated by hydrogen bonds, salt bridges, and van
der Waals interactions) [47]. Hereditary cataracts are caused by mutations that destabilize the
crystallin proteins, leading to the assembly of crystallins into amyloid-like fibers. For
example, the R120G mutation in αB-crystallin disrupts ionic interactions that normally
stabilize the αB-crystallin dimer (wild type αB-crystallin dimer is stabilized by a salt bridge
between R120 and D109) [48]. These studies with TTR (where the introduction of an
enthalpic interaction in the T119M variant hyper-stabilize the tetramer) and crystallins (where
disrupting an enthalpic interaction in the R120G variant destabilizes the dimer) suggest that
enthalpic forces controlling protein association could be similar to forces influencing
effective protein stabilization by small molecules such as AG10. This hypothesis would be
further supported by additional site-directed mutagenesis and structural studies to investigate
if factors other than enthalpy are also involved in the enhanced stabilization of TTR.
3.8 Conclusions
In summary, by analyzing the molecular interactions that stabilizers form with TTR
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and comparing it to interactions within stabilizing TTR mutations, we suggest that
electrostatic interactions formed deep in the T4 site of TTR (which could be similar to the
hydrogen bonds between S117/117’ of T119M-TTR and between the pyrazole of AG10 and
TTR) are more effective in stabilizing TTR compared to hydrophobic interaction and
interactions at the solvent exposed portion of the T4 pocket. There are limited examples
where the binding of a small molecule to a known disease-causing target mimics a stabilizing
mutation identified in that target protein. 34 In addition to stabilizing TTR, we hypothesize that
molecules with similar enthalpically-driven binding mode to that of AG10 could be useful in
stabilizing multi-subunit protein complexes in certain diseases such as crystallins in cataract
and α-synuclein tetramer in Parkinson’s Disease [49, 50].
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